Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

Previous PostRelmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder